NE3107

DRUG6 trials

Sponsors

BioVie Inc., Neurological Associates of West Los Angeles

Conditions

Alzheimer DiseaseLong COVIDParkinson DiseaseParkinsons Disease (PD)Traumatic Brain Injury

Phase 1

NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa

CompletedNCT05083260

BioVie Inc.Parkinson Disease

Start: 2022-01-04End: 2023-01-04Updated: 2023-02-08

Phase 2

Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia

CompletedNCT05227820

Neurological Associates of West Los AngelesAlzheimer Disease

Start: 2022-01-19End: 2022-08-20Updated: 2024-07-09

Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury

TerminatedNCT05970575

Neurological Associates of West Los AngelesTraumatic Brain Injury

Start: 2023-12-21End: 2025-07-21Updated: 2025-07-25

A Study of NE3107 in Early Parkinson's

CompletedNCT06757010

BioVie Inc.Parkinsons Disease (PD)

Start: 2025-03-26End: 2026-05-31Updated: 2026-08-11

NE3107 in Adults With Neurological Symptoms of Long COVID

Active, not recruitingNCT06847191

BioVie Inc.Long COVID

Start: 2025-04-29End: 2026-09-01Updated: 2026-08-26

Phase 3

A Phase 3 Study of NE3107 in Probable Alzheimer's Disease

CompletedNCT04669028

BioVie Inc.Alzheimer Disease

Start: 2021-08-05End: 2023-10-25Updated: 2023-11-21

Related Papers

ADDRESS-LC: study protocol for a phase 2, triple-blind, randomised, placebo-controlled trial to evaluate the efficacy and safety of bezisterim (NE3107) in adults with long COVID.

2026-07-24

An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease

Frontiers in Neuroscience2025-05-022 citations

Treatment‐Induced Epigenetic Modifications in MCI and Probable Alzheimer’s Disease

Alzheimer s & Dementia2023-12-011 citations

1520-P: Metabolic Dysregulation in Probable Alzheimer’s Disease

Diabetes2023-06-20

Rationale for an anti‐inflammatory insulin sensitizer in a phase 3 Alzheimer's disease trial

Alzheimer s & Dementia2021-12-012 citations

NM101 Phase III Study of NE3107 in Alzheimer’s Disease: rationale, Design and Therapeutic Modulation of Neuroinflammation and Insulin Resistance

Neurodegenerative Disease Management2021-07-1267 citations